Our results provide an acceptable promise to use hADSCs as a proper autologous adult stem cell population for cell replacement therapy of neurological disorders, but highlight the importance in the selection of cells that must have higher amounts of ATP6AP2 particularly in CLR-Ms for better response, thus emphasizing the crucial role of CLR-Ms. This evidence concerns the gene ATP6AP2 and nervous system disorder.